Global Viral Vector Manufacturing Market Size and Forecast 2024-2033|Sanofi S.A., Thermo Fisher Scientific Inc., Merck Group, FUJIFILM Holdings Corporation, Lonza Group

The Viral Vector Manufacturing Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Viral Vector Manufacturing Market:

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

According to The Business Research Company’s Viral Vector Manufacturing Global Market Report 2024, The viral vector manufacturing market size has grown exponentially in recent years. It will grow from $5.82 billion in 2023 to $7 billion in 2024 at a compound annual growth rate (CAGR) of 20.4%. The growth in the historic period can be attributed to growth in pipeline of gene therapies, clinical success and approvals, increased investment in biopharmaceuticals, increased prevalence of genetic disorders.

The viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $14.55 billion in 2028 at a compound annual growth rate (CAGR) of 20.0%. The growth in the forecast period can be attributed to expanding applications in oncology, global collaborations in gene therapy research, adoption of viral vectors in vaccine development, continued clinical trials and commercialization. Major trends in the forecast period include technological innovations in vector production, emergence of next-generation vectors, regulatory compliance and standardization, collaborations and partnerships, global expansion of manufacturing facilities.

The increase in the prevalence of cancer and infectious diseases is expected to propel the growth of the viral vector manufacturing market going forward. An infectious disease refers to a condition brought on by a virus or its toxic byproduct and spread to a susceptible host via contact with an infected person, animal, or item. Cancer refers to a broad range of illnesses that can develop in any organ or tissue of the body when aberrant cells grow out of control, cross their usual boundaries to invade neighbouring organs, and spread to other organs. Tumor antigens, or proteins on tumor cells, are produced via viral vectors to elicit the body’s anticancer immune response. In pre-clinical and clinical trials, viral vectors have served as vaccines against various infectious illnesses. For instance, in May 2022, according to the World Health Organization, a Switzerland-based specialized health agency, compared to 245 million cases in 2020, there were 247 million cases of malaria in 2021. Furthermore, in June 2023, according to the Centers for Disease Control and Prevention, a US-based Department of Health and Human Services, there were 1,603,844 new cancer cases and 602,347 cancer-related deaths in the US in 2020. Therefore, the increase in the prevalence of cancer and infectious diseases is driving the growth of the viral vector manufacturing market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12398&type=smp

The viral vector manufacturing market covered in this report is segmented –

1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types

2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases

3) By Workflow: Upstream Processing, Downstream Processing

4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research

5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users

Product innovation is a key trend gaining popularity in the viral vector manufacturing market. Major companies operating in the viral vector manufacturing market are introducing product innovations to sustain their position in the market. For instance, in August 2022, Merck KGaA, a German-based science and technology company, launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. One of the first Contract development and manufacturing organizations and technology creators to offer an entire viral vector manufacturing package, including AAV, Lentiviral, CDMO, CTO, and process development. With the help of this innovative platform, biopharmaceutical businesses may shorten the time and expense of process development while accelerating the time to clinical manufacture

The viral vector manufacturing market report table of contents includes:

1. Executive Summary

2. Viral Vector Manufacturing Market Characteristics

3. Viral Vector Manufacturing Market Trends And Strategies

4. Viral Vector Manufacturing Market – Macro Economic Scenario

5. Global Viral Vector Manufacturing Market Size and Growth

26. South America Viral Vector Manufacturing Market

27. Brazil Viral Vector Manufacturing Market

28. Middle East Viral Vector Manufacturing Market

29. Africa Viral Vector Manufacturing Market

30. Viral Vector Manufacturing Market Competitive Landscape And Company Profiles

Top Major Players: